Effect of coadministration of vancomycin and BMP-2 on cocultured Staphylococcus aureus and W-20-17 mouse bone marrow stromal cells in vitro

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3776-3784

  Nguyen, A H ^a   Kim, S ^a,b   Maloney, W J ^b   Wenke, J C ^c   Yang, Y ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b STANFORD UNIVERSITY   (United States)

^c US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; DOUBLE STRANDED DNA; INTERLEUKIN 6; VANCOMYCIN;

ANIMAL CELL; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BONE MARROW CELL; BONE MARROW STROMAL CELL; CELL DIFFERENTIATION; CELL INVASION; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; INFLAMMATION; METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS; MONOCULTURE; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; MICE; STAPHYLOCOCCUS AUREUS; STROMAL CELLS; VANCOMYCIN;

EID: 84862528362     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00114-12     Document Type: Article

References (50)

1. Ackerman BH, Vannier AM, Eudy EB. 1992. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob. Agents Chemother. 36:1766-1769.
2. Ako-Nai AK, Ikem IC, Daniel FV, Ojo DO, Oginni LM. 2009. A comparison of superficial and deep bacterial presence in open fractures of the lower extremities. Int. J. Low. Extrem. Wounds 8:197-202.
3. Alexander EH, Hudson MC. 2001. Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. Appl. Microbiol. Biotechnol. 56:361-366.
4. Allen RT, Lee YP, Stimson E, Garfin SR. 2007. Bone morphogenetic protein-2 (BMP-2) in treatment of pyogenic vertebral osteomyelitis. Spine (Phila Pa 1976) 32:2996-3006.
5. Barna JC, Williams DH. 1984. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 38:339-357.
6. Bost KL, et al. 1999. Staphylococcus aureus infection of mouse or human osteoblasts induces high levels of interleukin-6 and interleukin-12 production. J. Infect. Dis. 180:1912-1920.
7. Boyce T, Edwards J, Scarborough N. 1999. Allograft bone. The influence of processing on safety and performance. Orthop. Clin. North Am. 30:571-581.
8. Ciampolini J, Harding KG. 2000. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad. Med. J. 76:479-483.
9. Cornell CN, Tyndall D, Waller S, Lane JM, Brause BD. 1993. Treatment of experimental osteomyelitis with antibiotic-impregnated bone graft substitute. J. Orthop. Res. 11:619-626.
10. Covey DC, et al. 2008. Orthopaedic war injuries: from combat casualty care to definitive treatment: a current review of clinical advances, basic science, and research opportunities. Instr. Course Lect. 57:65-86.
11. Ellington JK, Elhofy A, Bost KL, Hudson MC. 2001. Involvement of mitogen-activated protein kinase pathways in Staphylococcus aureus invasion of normal osteoblasts. Infect. Immun. 69:5235-5242.
12. Ellington JK, et al. 2006. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J. Orthop. Res. 24:87-93.
13. Ellington JK, et al. 1999. Mechanisms of Staphylococcus aureus invasion of cultured osteoblasts. Microb. Pathog. 26:317-323.
14. Elsalanty ME, et al. 2008. Recombinant human BMP-2 enhances the effects of materials used for reconstruction of large cranial defects. J. Oral Maxillofac. Surg. 66:277-285.
15. Garzoni C, Kelley WL. 2009. Staphylococcus: new evidence for intracellular persistence. Trends Microbiol. 17:59-65.
16. Ginebra P, Traykova T, Planell JA. 2006. Calcium phosphate cements as bone drug delivery systems: a review. J. Control Release 113:102-110.
17. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. 1988. Vancomycin concentrations in infected and noninfected human bone. Antimicrob. Agents Chemother. 32:1320-1322.
18. Guelcher SA, et al. 2011. Dual-purpose bone grafts improve healing and reduce infection. J. Orthop. Trauma 25:477-482.
19. Gustilo RB, Anderson JT. 1976. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analysis. J. Bone Joint Surg. Am. 58:453-458.
20. Hanada K, Dennis JE, Caplan AI. 1997. Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. J. Bone Miner. Res. 12:1606-1614.
21. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 116:2138-2144.
22. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. 2007. Infectious complications of open type III tibial fractures among combat casualties. Clin. Infect. Dis. 45:409-415.
23. Kempen DH, et al. 2008. Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials 29:3245-3252.
24. Ketonis C, et al. 2010. Antibiotic modification of native grafts: improving upon nature's scaffolds. Tissue Eng. Part A 16:2041-2049.
25. Ketonis C, et al. 2011. Vancomycin bonded to bone grafts prevents bacterial colonization. Antimicrob. Agents Chemother. 55:487-494.
26. Kim S, et al. 2011. In vitro evaluation of an injectable chitosan gel for sustained local delivery of BMP-2 for osteoblastic differentiation. J. Biomed. Mater. Res. B Appl. Biomater. 99:380-390.
27. Liu SJ, et al. 2007. Novel solvent-free fabrication of biodegradable polylactic-glycolic acid (PLGA) capsules for antibiotics and rhBMP-2 delivery. Int. J. Pharm. 330:45-53.
28. Liu Y, Huse RO, de Groot K, Buser D, Hunziker EB. 2007. Delivery mode and efficacy of BMP-2 in association with implants. J. Dent. Res. 86:84-89.
29. Lord CF, Gebhardt MC, Tomford WW, Mankin HJ. 1988. Infection of bone allografts. J. Bone Joint Surg. Am. 70:369-376.
30. Menzies BE, Kourteva I. 1998. Internalization of staphylococcus aureus by endothelial cells induces apoptosis. Infect. Immun. 66:5994-5998.
31. Murray CK, et al. 2011. Prevention of infections associated with combat-related extremity injuries. J. Trauma 71(Suppl. 2):S235-S257.
32. Nair SP, Williams RJ, Henderson B. 2000. Advances in our understanding of the bone and joint pathology caused by Staphylococcus aureus infection. Rheumatology (Oxford) 39:821-834.
33. Owens BD, et al. 2008. Combat wounds in operation Iraqi Freedom and operation Enduring Freedom. J. Trauma 64:295-299.
34. Raiche AT, Puleo DA. 2004. Cell responses to BMP-2 and IGF-1 released with different time-dependent profiles. J. Biomed. Mater. Res. A 69:342-350.
35. Rathbone CR, Cross JD, Brown KV, Murray CK, Wenke JC. 2011. Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J. Orthop. Res. 29:1070-1074.
36. Reilly SS, Hudson MC, Kellam JF, Ramp WK. 2000. In vivo internalization of Staphylococcus aureus by embryonic chick osteoblasts. Bone 26:63-70.
37. Riew KD, Wright NM, Cheng S, Avioli LV, Lou J. 1998. Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif. Tissue Int. 63:357-360.
38. Rose WE, Poppens PT. 2009. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 63:485-488.
39. Smith TL, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med. 340:493-501.
40. Soriano A, et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
41. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. 1982. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. 97:344-350.
42. Stinner DJ, Waterman SM, Masini BD, Wenke JC. 2011. Silver dressings augment the ability of negative pressure wound therapy to reduce bacteria in a contaminated open fracture model. J. Trauma 71(Suppl.):S147-S150.
43. Tenover FC, Moellering RC, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215.
44. Tucker KA, Reilly SS, Leslie CS, Hudson MC. 2000. Intracellular Staphylococcus aureus induces apoptosis in mouse osteoblasts. FEMS Microbiol. Lett. 186:151-156.
45. Wang Y, et al. 2011. Assessing the character of the rhBMP-2 and vancomycin-loaded calcium sulphate composites in vitro and in vivo. Arch. Orthop. Trauma Surg. 131:991-1001.
46. Wenke JC, Guelcher SA. 2011. Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures. Expert Opin. Drug Deliv. 8:1555-1569.
47. Winkler H, Janata O, Berger C, Wein W, Georgopoulos A. 2000. In vitro release of vancomycin and tobramycin from impregnated human and bovine bone grafts. J. Antimicrob. Chemother. 46:423-428.
48. Younger EM, Chapman MW. 1989. Morbidity at bone graft donor sites. J. Orthop. Trauma 3:192-195.
49. Zheng Z, et al. 2010. The use of BMP-2 coupled-Nanosiver-PLGA composite grafts to induce bone repair in grossly infected segmental defects. Biomaterials 31:9293-9300.
50. Zilberman M, Elsner JJ. 2008. Antibiotic-eluting medical devices for various applications. J. Control Release 130:202-215.